According to a recent LinkedIn post from AAVantgarde Bio, the company has brought on Philip Lao as Senior Vice President of Business Development. The post suggests that Lao will focus on expanding strategic partnerships and commercial opportunities for the firm’s pipeline of retinal therapeutics.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
The LinkedIn post also points to in‑development programs targeting Usher 1B and Stargardt disease, indicating ongoing investment in inherited retinal disorder therapeutics. For investors, the appointment of a senior business development leader may signal a greater emphasis on partnership-driven growth, potential licensing deals, and future revenue streams tied to these clinical assets.